

**Innovative AMDC Breakthrough: New Hope in Targeted Cancer Treatment**

Tokyo, Japan, October 20, 2023 — A game-changing advancement in cancer therapy is on the horizon. Savid Therapeutics and scientists from the University of Tokyo and Tohoku University have unveiled a groundbreaking Antibody-Mimetic Drug Conjugate (AMDC) that can overcome longstanding challenges in cancer treatment.

**The AMDC Solution**

This research introduces an ingenious solution to the hurdles associated with post-translational modification of proteins, complex manufacturing process and variability in the internalization in cancer cells. The key lies in a method that fuses a monomeric anti-HER2 VHH to “Cupid”, resulting in "anti-HER2 VHH-Cupid." This tetrameric protein can be conveniently purified based on molecular weight, which streamlines production in manufacturing.

**A Potent Complex: Duo-HER2 (STI-002)**

Anti-HER2 VHH-Cupid non-covalently binds with "Psyche" linked to a potent DNA-alkylating agent, duocarmycin. This complex effectively targets and destroys HER2-expressing human cancer cells in vitro and in vivo, ushering in a new era of cancer treatment.

**Promising Cancer Therapy Platform**

Savid’s AMDC technology promises to revolutionize cancer therapy by combining targeting precision with potent payloads and streamlined manufacturing. Researchers anticipate significant improvements in patient outcomes and a reduction in traditional treatment side effects.

**For media inquiries or more information, please contact:**

**Michael Chansler, Vice President Business Development, Savid Therapeutics, Inc. mchansler@savidtherapeutics.com**